81-OR: Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology
Introduction & Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in patients with T2D. We have assessed the diagnostic performance of non-invasive tests (NITs) and pathways recommended by AASLD guidelines in dia...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73 (Supplement_1), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | 1 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 73 |
| creator | CAUSSY, CYRIELLE VERGÈS, BRUNO LELEU, DAMIEN DUVILLARD, LAURENCE ABICHOU-KLICH, AMNA SEGRESTIN, BERENICE BIN, SYLVIE ROULAND, ALEXIA DELAUNAY, DOMINIQUE HADJADJ, SAMY PRIMOT, CLAIRE PETIT, JEAN-MICHEL CHARRIÈRE, SYBIL MOULIN, PHILIPPE LEVRERO, MASSIMO CARIOU, BERTRAND DISSE, EMMANUEL |
| description | Introduction & Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in patients with T2D. We have assessed the diagnostic performance of non-invasive tests (NITs) and pathways recommended by AASLD guidelines in diabetology.
Methods: Interim analysis from a multicenter prospective study including 568 patients with T2D and MASLD, age 40-80 years, BMI |
| doi_str_mv | 10.2337/db24-81-OR |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3100300194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3100300194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c634-90f41109d84089f571107b26ce401c902b3b1cb09b20754e8f8a2249bd0d1dfe3</originalsourceid><addsrcrecordid>eNotkE1PAjEQhhujiYhe_AVNvJmsTj-gW28ERE0wGODArenXYglssV00_HsXMXOYzOTJO--8CN0SeKCMiUdnKC9KUkxnZ6hDJJMFo2J5jjoAhBZESHGJrnJeA0C_rQ5a_sFPeBi3O51CjjWOFZ7b5H0d6hX-0M3njz7k43bgvnVtvcPjYFLMIePR3uMm4vfBfDLCocajoI1v4iauDtfootKb7G_-exctxs-L4Wsxmb68DQeTwvYZLyRUnBCQruRQyqon2kEY2reeA7ESqGGGWAPSUBA97suq1JRyaRw44irPuujuJLtL8Wvvc6PWcZ_q9qJiBIC1f0veUvcnyra-c_KV2qWw1emgCKhjcOoYnCqJms7YL-ItXhs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3100300194</pqid></control><display><type>article</type><title>81-OR: Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>CAUSSY, CYRIELLE ; VERGÈS, BRUNO ; LELEU, DAMIEN ; DUVILLARD, LAURENCE ; ABICHOU-KLICH, AMNA ; SEGRESTIN, BERENICE ; BIN, SYLVIE ; ROULAND, ALEXIA ; DELAUNAY, DOMINIQUE ; HADJADJ, SAMY ; PRIMOT, CLAIRE ; PETIT, JEAN-MICHEL ; CHARRIÈRE, SYBIL ; MOULIN, PHILIPPE ; LEVRERO, MASSIMO ; CARIOU, BERTRAND ; DISSE, EMMANUEL</creator><creatorcontrib>CAUSSY, CYRIELLE ; VERGÈS, BRUNO ; LELEU, DAMIEN ; DUVILLARD, LAURENCE ; ABICHOU-KLICH, AMNA ; SEGRESTIN, BERENICE ; BIN, SYLVIE ; ROULAND, ALEXIA ; DELAUNAY, DOMINIQUE ; HADJADJ, SAMY ; PRIMOT, CLAIRE ; PETIT, JEAN-MICHEL ; CHARRIÈRE, SYBIL ; MOULIN, PHILIPPE ; LEVRERO, MASSIMO ; CARIOU, BERTRAND ; DISSE, EMMANUEL</creatorcontrib><description>Introduction & Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in patients with T2D. We have assessed the diagnostic performance of non-invasive tests (NITs) and pathways recommended by AASLD guidelines in diabetology.
Methods: Interim analysis from a multicenter prospective study including 568 patients with T2D and MASLD, age 40-80 years, BMI <40 kg/m2 from 4 French diabetes clinics between Oct. 2020 and Oct. 2023. All participants had a detailed liver assessment: Fibrotest, FibroMeter, FIB-4, NFS, ELF and transient elastography (TE) by FibroScan. A low/high risk of AF was defined by a hierarchical composite criterion Fig.
Results: The characteristics were: hypertension: 71%, male 58%, mean age: 60.5 years and BMI: 32.1 kg/m2. Overall, 19% had intermediate/high risk of AF including 10% at high risk. The AUROCs of NITs for the detection of high risk AF were: NFS: 0.70, FIB-4: 0.79, Fibrometer: 0.72, Fibrotest: 0.77, ELF: 0.82. AASLD pathway using ELF classified 81.5% at low risk with 9.4% false negative (FN); 18.5% needed hepatology care with 9.1% true positive (TP). Pathway using TE classified 85.4% at low risk with 5.1% FN; 14.6% needed hepatology care with 13.3% TP (Fig).
Conclusion: Recommended AASLD pathways have a good diagnostic performance in diabetology to identify AF and the use of TE is preferable depending on availability.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db24-81-OR</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Diabetes mellitus ; Fibrosis ; Hepatology ; Liver diseases</subject><ispartof>Diabetes (New York, N.Y.), 2024-06, Vol.73 (Supplement_1), p.1</ispartof><rights>Copyright American Diabetes Association Jun 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>CAUSSY, CYRIELLE</creatorcontrib><creatorcontrib>VERGÈS, BRUNO</creatorcontrib><creatorcontrib>LELEU, DAMIEN</creatorcontrib><creatorcontrib>DUVILLARD, LAURENCE</creatorcontrib><creatorcontrib>ABICHOU-KLICH, AMNA</creatorcontrib><creatorcontrib>SEGRESTIN, BERENICE</creatorcontrib><creatorcontrib>BIN, SYLVIE</creatorcontrib><creatorcontrib>ROULAND, ALEXIA</creatorcontrib><creatorcontrib>DELAUNAY, DOMINIQUE</creatorcontrib><creatorcontrib>HADJADJ, SAMY</creatorcontrib><creatorcontrib>PRIMOT, CLAIRE</creatorcontrib><creatorcontrib>PETIT, JEAN-MICHEL</creatorcontrib><creatorcontrib>CHARRIÈRE, SYBIL</creatorcontrib><creatorcontrib>MOULIN, PHILIPPE</creatorcontrib><creatorcontrib>LEVRERO, MASSIMO</creatorcontrib><creatorcontrib>CARIOU, BERTRAND</creatorcontrib><creatorcontrib>DISSE, EMMANUEL</creatorcontrib><title>81-OR: Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology</title><title>Diabetes (New York, N.Y.)</title><description>Introduction & Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in patients with T2D. We have assessed the diagnostic performance of non-invasive tests (NITs) and pathways recommended by AASLD guidelines in diabetology.
Methods: Interim analysis from a multicenter prospective study including 568 patients with T2D and MASLD, age 40-80 years, BMI <40 kg/m2 from 4 French diabetes clinics between Oct. 2020 and Oct. 2023. All participants had a detailed liver assessment: Fibrotest, FibroMeter, FIB-4, NFS, ELF and transient elastography (TE) by FibroScan. A low/high risk of AF was defined by a hierarchical composite criterion Fig.
Results: The characteristics were: hypertension: 71%, male 58%, mean age: 60.5 years and BMI: 32.1 kg/m2. Overall, 19% had intermediate/high risk of AF including 10% at high risk. The AUROCs of NITs for the detection of high risk AF were: NFS: 0.70, FIB-4: 0.79, Fibrometer: 0.72, Fibrotest: 0.77, ELF: 0.82. AASLD pathway using ELF classified 81.5% at low risk with 9.4% false negative (FN); 18.5% needed hepatology care with 9.1% true positive (TP). Pathway using TE classified 85.4% at low risk with 5.1% FN; 14.6% needed hepatology care with 13.3% TP (Fig).
Conclusion: Recommended AASLD pathways have a good diagnostic performance in diabetology to identify AF and the use of TE is preferable depending on availability.</description><subject>Diabetes mellitus</subject><subject>Fibrosis</subject><subject>Hepatology</subject><subject>Liver diseases</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNotkE1PAjEQhhujiYhe_AVNvJmsTj-gW28ERE0wGODArenXYglssV00_HsXMXOYzOTJO--8CN0SeKCMiUdnKC9KUkxnZ6hDJJMFo2J5jjoAhBZESHGJrnJeA0C_rQ5a_sFPeBi3O51CjjWOFZ7b5H0d6hX-0M3njz7k43bgvnVtvcPjYFLMIePR3uMm4vfBfDLCocajoI1v4iauDtfootKb7G_-exctxs-L4Wsxmb68DQeTwvYZLyRUnBCQruRQyqon2kEY2reeA7ESqGGGWAPSUBA97suq1JRyaRw44irPuujuJLtL8Wvvc6PWcZ_q9qJiBIC1f0veUvcnyra-c_KV2qWw1emgCKhjcOoYnCqJms7YL-ItXhs</recordid><startdate>20240614</startdate><enddate>20240614</enddate><creator>CAUSSY, CYRIELLE</creator><creator>VERGÈS, BRUNO</creator><creator>LELEU, DAMIEN</creator><creator>DUVILLARD, LAURENCE</creator><creator>ABICHOU-KLICH, AMNA</creator><creator>SEGRESTIN, BERENICE</creator><creator>BIN, SYLVIE</creator><creator>ROULAND, ALEXIA</creator><creator>DELAUNAY, DOMINIQUE</creator><creator>HADJADJ, SAMY</creator><creator>PRIMOT, CLAIRE</creator><creator>PETIT, JEAN-MICHEL</creator><creator>CHARRIÈRE, SYBIL</creator><creator>MOULIN, PHILIPPE</creator><creator>LEVRERO, MASSIMO</creator><creator>CARIOU, BERTRAND</creator><creator>DISSE, EMMANUEL</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20240614</creationdate><title>81-OR: Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology</title><author>CAUSSY, CYRIELLE ; VERGÈS, BRUNO ; LELEU, DAMIEN ; DUVILLARD, LAURENCE ; ABICHOU-KLICH, AMNA ; SEGRESTIN, BERENICE ; BIN, SYLVIE ; ROULAND, ALEXIA ; DELAUNAY, DOMINIQUE ; HADJADJ, SAMY ; PRIMOT, CLAIRE ; PETIT, JEAN-MICHEL ; CHARRIÈRE, SYBIL ; MOULIN, PHILIPPE ; LEVRERO, MASSIMO ; CARIOU, BERTRAND ; DISSE, EMMANUEL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c634-90f41109d84089f571107b26ce401c902b3b1cb09b20754e8f8a2249bd0d1dfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Diabetes mellitus</topic><topic>Fibrosis</topic><topic>Hepatology</topic><topic>Liver diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CAUSSY, CYRIELLE</creatorcontrib><creatorcontrib>VERGÈS, BRUNO</creatorcontrib><creatorcontrib>LELEU, DAMIEN</creatorcontrib><creatorcontrib>DUVILLARD, LAURENCE</creatorcontrib><creatorcontrib>ABICHOU-KLICH, AMNA</creatorcontrib><creatorcontrib>SEGRESTIN, BERENICE</creatorcontrib><creatorcontrib>BIN, SYLVIE</creatorcontrib><creatorcontrib>ROULAND, ALEXIA</creatorcontrib><creatorcontrib>DELAUNAY, DOMINIQUE</creatorcontrib><creatorcontrib>HADJADJ, SAMY</creatorcontrib><creatorcontrib>PRIMOT, CLAIRE</creatorcontrib><creatorcontrib>PETIT, JEAN-MICHEL</creatorcontrib><creatorcontrib>CHARRIÈRE, SYBIL</creatorcontrib><creatorcontrib>MOULIN, PHILIPPE</creatorcontrib><creatorcontrib>LEVRERO, MASSIMO</creatorcontrib><creatorcontrib>CARIOU, BERTRAND</creatorcontrib><creatorcontrib>DISSE, EMMANUEL</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CAUSSY, CYRIELLE</au><au>VERGÈS, BRUNO</au><au>LELEU, DAMIEN</au><au>DUVILLARD, LAURENCE</au><au>ABICHOU-KLICH, AMNA</au><au>SEGRESTIN, BERENICE</au><au>BIN, SYLVIE</au><au>ROULAND, ALEXIA</au><au>DELAUNAY, DOMINIQUE</au><au>HADJADJ, SAMY</au><au>PRIMOT, CLAIRE</au><au>PETIT, JEAN-MICHEL</au><au>CHARRIÈRE, SYBIL</au><au>MOULIN, PHILIPPE</au><au>LEVRERO, MASSIMO</au><au>CARIOU, BERTRAND</au><au>DISSE, EMMANUEL</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>81-OR: Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2024-06-14</date><risdate>2024</risdate><volume>73</volume><issue>Supplement_1</issue><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Introduction & Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in patients with T2D. We have assessed the diagnostic performance of non-invasive tests (NITs) and pathways recommended by AASLD guidelines in diabetology.
Methods: Interim analysis from a multicenter prospective study including 568 patients with T2D and MASLD, age 40-80 years, BMI <40 kg/m2 from 4 French diabetes clinics between Oct. 2020 and Oct. 2023. All participants had a detailed liver assessment: Fibrotest, FibroMeter, FIB-4, NFS, ELF and transient elastography (TE) by FibroScan. A low/high risk of AF was defined by a hierarchical composite criterion Fig.
Results: The characteristics were: hypertension: 71%, male 58%, mean age: 60.5 years and BMI: 32.1 kg/m2. Overall, 19% had intermediate/high risk of AF including 10% at high risk. The AUROCs of NITs for the detection of high risk AF were: NFS: 0.70, FIB-4: 0.79, Fibrometer: 0.72, Fibrotest: 0.77, ELF: 0.82. AASLD pathway using ELF classified 81.5% at low risk with 9.4% false negative (FN); 18.5% needed hepatology care with 9.1% true positive (TP). Pathway using TE classified 85.4% at low risk with 5.1% FN; 14.6% needed hepatology care with 13.3% TP (Fig).
Conclusion: Recommended AASLD pathways have a good diagnostic performance in diabetology to identify AF and the use of TE is preferable depending on availability.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db24-81-OR</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2024-06, Vol.73 (Supplement_1), p.1 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_3100300194 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Diabetes mellitus Fibrosis Hepatology Liver diseases |
| title | 81-OR: Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A11%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=81-OR:%20Comparison%20of%20Screening%20Pathways%20of%20Advanced%20Fibrosis%20Due%20to%20MASLD%20in%20Diabetology&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=CAUSSY,%20CYRIELLE&rft.date=2024-06-14&rft.volume=73&rft.issue=Supplement_1&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db24-81-OR&rft_dat=%3Cproquest_cross%3E3100300194%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3100300194&rft_id=info:pmid/&rfr_iscdi=true |